{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:34:33Z","timestamp":1761168873420,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.jval.2013.05.002","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T10:01:16Z","timestamp":1373536876000},"page":"769-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Gastroprotective Strategies in Chronic NSAID Users: A Cost-Effectiveness Analysis Comparing Single-Tablet Formulations with Individual Components"],"prefix":"10.1016","volume":"16","author":[{"given":"N.L.","family":"de Groot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.R.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.G.M","family":"van Haalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.J.","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.D.","family":"Siersema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.H.","family":"van Oijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2013.05.002_bib1","unstructured":"National Institute for Health and Clinical Excellence. Osteoarthritis: The Care and Management of Osteoarthritis in Adults. NICE clinical guideline 59. London, UK: National Institute for Health and Clinical Excellence, 2008."},{"key":"10.1016\/j.jval.2013.05.002_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/ard.2004.028886","article-title":"EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"64","author":"Zhang","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2013.05.002_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1053\/j.gastro.2006.12.007","article-title":"Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population","volume":"132","author":"Garcia Rodriguez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2013.05.002_bib4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/00019053-200119060-00004","article-title":"An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands","volume":"19","author":"Herings","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2013.05.002_bib5","first-page":"728","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2013.05.002_bib6","doi-asserted-by":"crossref","first-page":"b2538","DOI":"10.1136\/bmj.b2538","article-title":"Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis","volume":"339","author":"Latimer","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2013.05.002_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.21065","article-title":"Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups","volume":"53","author":"Spiegel","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2013.05.002_bib8","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Scheiman J, Abraham NS, et al. ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894\u2013909.","DOI":"10.1161\/CIRCULATIONAHA.108.191087"},{"key":"10.1016\/j.jval.2013.05.002_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group","volume":"338","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.05.002_bib10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"1520\u20138","key":"10.1016\/j.jval.2013.05.002_bib11","first-page":"2","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"VIGOR Study Group. N Engl J Med"},{"key":"10.1016\/j.jval.2013.05.002_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-138-10-200305200-00007","article-title":"The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis","volume":"138","author":"Spiegel","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2013.05.002_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2036.2009.04090.x","article-title":"Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines","volume":"30","author":"Laine","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.cgh.2006.08.016","article-title":"Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications","volume":"4","author":"Goldstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jval.2013.05.002_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01795.x","article-title":"Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs","volume":"18","author":"Sturkenboom","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2007.03358.x","article-title":"Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage","volume":"26","author":"Van Soest","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2036.2010.04378.x","article-title":"Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone","volume":"32","author":"Goldstein","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib18","doi-asserted-by":"crossref","first-page":"A-67","DOI":"10.1016\/S0016-5085(09)60310-3","article-title":"Does high-dose famotidine reduce gastric and duodenal ulcers in NSAID users? Two double-blind six month trials of single-tablet combination ibuprofen-famotidine vs ibuprofenalone (Reduce-1 and 2)","volume":"136","author":"Laine","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2013.05.002_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1524-4733.2007.00303.x","article-title":"Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands","volume":"11","author":"Al","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2013.05.002_bib20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3899\/jrheum.090812","article-title":"Mortality and predictors of mortality in rheumatoid arthritis\u2014a role for mannose-binding lectin?","volume":"37","author":"Troelsen","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jval.2013.05.002_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ajg.2009.507","article-title":"Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases","volume":"105","author":"Sung","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2013.05.002_bib22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/j.1365-2036.2006.03139.x","article-title":"Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors","volume":"24","author":"Thomsen","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib23","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2013.05.002_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/art.11192","article-title":"Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs","volume":"49","author":"Ofman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2013.05.002_bib25","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2013.05.002_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2005.11.020","article-title":"Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis","volume":"119","author":"Spiegel","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jval.2013.05.002_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2013.05.002_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/rheumatology\/kel223","article-title":"Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study","volume":"46","author":"Rahme","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jval.2013.05.002_bib29","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations","volume":"55","author":"Lanas","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jval.2013.05.002_bib30","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cgh.2007.03.011","article-title":"Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review","volume":"5","author":"Rostom","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jval.2013.05.002_bib31","doi-asserted-by":"crossref","DOI":"10.3310\/hta11510","article-title":"Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding","volume":"11","author":"Leontiadis","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2013.05.002_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","article-title":"Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials","volume":"325","author":"Deeks","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2013.05.002_bib33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pds.1639","article-title":"Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib","volume":"17","author":"Patterson","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2013.05.002_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1572-0241.2001.03516.x","article-title":"Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia","volume":"96","author":"Groeneveld","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2013.05.002_bib35","first-page":"545","article-title":"Evaluation of the dyspeptic patient: a cost-utility study","volume":"44","author":"Ebell","year":"1997","journal-title":"J Fam Pract"},{"key":"10.1016\/j.jval.2013.05.002_bib36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-150-7-200904070-00105","article-title":"Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial","volume":"150","author":"Sung","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2013.05.002_bib37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.gie.2008.10.051","article-title":"Changing trends in acute upper-GI bleeding: a population-based study","volume":"70","author":"Loperfido","year":"2009","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jval.2013.05.002_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bpg.2007.10.011","article-title":"Epidemiology of acute upper gastrointestinal bleeding","volume":"22","author":"van Leerdam","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jval.2013.05.002_bib39","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1572-0241.2005.41465.x","article-title":"Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors","volume":"100","author":"Hawkey","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2013.05.002_bib40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2036.2006.03210.x","article-title":"Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs","volume":"25","author":"Hawkey","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2036.1998.0284f.x","article-title":"First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid\/alginate liquid: a multicentre study in general practice","volume":"12","author":"Goves","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib42","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/j.1572-0241.2006.00751.x","article-title":"Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled \u201cENTER: trial","volume":"101","author":"van Zanten","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2013.05.002_bib43","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","article-title":"Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis","volume":"347","author":"Chan","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.05.002_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00019053-199711020-00005","article-title":"Guidelines for pharmacoeconomic studies: recommendations from the Panel on Cost-Effectiveness in Health and Medicine. Panel on Cost- Effectiveness in Health and Medicine","volume":"11","author":"Siegel","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2013.05.002_bib45","article-title":"Economic evaluation of prevention: opportunities for Dutch public health policy","author":"Vijgen","year":"2005","journal-title":"Bilthoven, NL: RIVM"},{"key":"10.1016\/j.jval.2013.05.002_bib46","unstructured":"Dutch Healthcare Authority. Available from: www.nza.nl. [Accessed February 1, 2012]."},{"key":"10.1016\/j.jval.2013.05.002_bib47","unstructured":"Health Care Insurance Board. Available from: www.medicijnkosten.nl. [Accessed February 1, 2012]."},{"key":"10.1016\/j.jval.2013.05.002_bib48","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2036.2010.04465.x","article-title":"Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients","volume":"32","author":"Laine","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib49","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1365-2036.2010.04305.x","article-title":"Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents","volume":"31","author":"Cameron","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2013.05.002_bib50","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/gut.2011.239848","article-title":"Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases","volume":"60","author":"Van Soest","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jval.2013.05.002_bib51","first-page":"44","article-title":"Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout","volume":"30","author":"de Klerk","year":"2003","journal-title":"J Rheumatol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301513018184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301513018184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:12:22Z","timestamp":1761095542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301513018184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1098301513018184"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2013.05.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastroprotective Strategies in Chronic NSAID Users: A Cost-Effectiveness Analysis Comparing Single-Tablet Formulations with Individual Components","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2013.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}